




PRESTIGE BIOPHARMA
**INNOVATION
FOR LIFE**



A FRONTIER IN BIOPHARMACEUTICALS

Specializing in development of biosimilars and antibody drugs



United States
Prestige Biopharma
USA

Europe
Prestige Biopharma
Belgium

South Korea
Innovative Discovery Center, Busan
Prestige Biologics GMP Plant, Osong

Singapore
Global Center

Prestige Biopharma is one of the fastest growing biopharmaceuticals focusing on the development of biosimilars and first-in-class antibody drugs as well as vaccines for infectious diseases.

With our R&D and operational experience in drug discovery, we expedite future biologics development and commercialization in a concerted approach based on our proprietary technologies and scientific capabilities.




Research Center in Biopolis, Singapore



Our CDMO Partner, Prestige Biologics (**Plant 1 : PIONEER, Plant 2 : FRONTIER, Plant 3 : VOYAGER, Plant 4 : ADVENTURE**)

PAVING THE WAY TO DELIVER OUR VALUES FOR PATIENTS









FULL VALUE CHAIN TECHNOLOGICAL PLATFORM FOR DRUG DISCOVERY LEADING TO EXPEDITED DEVELOPMENT





Biosimilar Pipeline

Prestige Biopharma aims to expand patient access to treatment by providing safe, quality and affordable biomedicines. Prestige’s biosimilar portfolio includes trastuzumab in completion of Phase III, bevacizumab in Phase III and adalimumab in Phase I. Based on the technologies and capabilities established from the successful development of these biosimilars, the next tier of biosimilars as well as new antibody therapeutics are under development.

Trade Name	INN / Therapeutic Area	Development Stage
Herceptin®	Trastuzumab Oncology 	Filing (EU) 
Avastin®	Bevacizumab Oncology 	Clinical (Phase 3) 
Humira®	Adalimumab Immunology 	Clinical (Phase 1) 
Prolia®	Denosumab Endocrinology	Preclinical
Eylea®	Aflibercept Ophthalmology	Preclinical
Opdivo®	Nivolumab Oncology	Discovery
Keytruda®	Pembrolizumab Oncology	Discovery
Soliris®	Eculizumab Immunology	Discovery
Yervoy®	Ipilimumab Oncology	Discovery
Perjeta®	Pertuzumab Oncology	Discovery
Hemlibra®	Emicizumab Hematology	Discovery
Stelara®	Ustekinumab Immunology	Discovery
Trulicity®	Dulaglutide Endocrinology	Discovery
Ocrevus®	Ocrelizumab Immunology	Discovery
Entyvio®	Vedolizumab Immunology	Discovery

First-in-Class Antibody Pipeline

Development of innovative first-in-class bispecific antibody drugs based on proprietary novel therapeutics, 'ulenistamab' and 'anti-CTHRC1'.

Category	Pipeline	Indication	Development Stage
First-in-Class	PBP1510 Ulenistamab	Pancreatic cancer, Ovarian cancer	Clinical (Phase 1/2a) 
	PBP1710 Anti-CTHRC1	Solid tumor	Preclinical 
	IDC111	Solid tumor	Basic Research
Bispecific Antibody	IDC001	Solid tumor	Basic Research
	IDC002	Solid tumor	Basic Research
	IDC003	Solid tumor	Basic Research
	IDC005	Solid tumor	Discovery
	IDC007	Critical immune disorders	Discovery
	IDC008	Solid tumor	Discovery
	IDC009	Solid tumor	Discovery
	IDC010	Immune disease	Discovery
Novel Concept Antibody	IDC331	Solid tumor	Discovery
	IDC332	Solid tumor	Discovery
	IDC333	Solid tumor	Discovery
	IDC334	Solid tumor	Discovery
Antibody Drug Conjugate	IDC441	Solid tumor	Basic Research

OPEN INNOVATION HUB

Located in Busan, South Korea, IDC aims to establish an open innovation platform by fostering synergy between science and technology, implementing a comprehensive innovative drug platform ('Plug and Play') and offering shared lab opportunities.

FOCUS

IDC focuses on developing first-in-class therapeutic antibodies to address unmet medical needs.

Innovative Discovery Center

Prestige Biopharma IDC

WE EMBRACE OUR NEW FUTURE WITH:

Rich portfolio of biosimilars and first-in-class antibody drugs

World-class Innovative Discovery Center with cutting-edge scientific infrastructure for first-in-class biologics research and development

What seems impossible can be made possible with innovative, creative and tenacious approaches.

We continue to challenge ourselves and stay current by being focused on bringing affordable medicines of superior quality and new cures to fight devastating diseases.

Prestige Biopharma IDC's top-notch, all encompassing technology as well as outreach to industry peers and academia enables accelerated drug discovery and development, thereby contributing to improving human health and access to medicines.

CREATING DIFFERENCES AND VALUE FOR HUMAN HEALTH



Prestige Biopharma strives to improve accessibility and affordability of existing biologic drugs as well as to develop new drugs for life-threatening diseases, paving the way to making real differences in the lives of humans all around the world.

OUR MISSION

To be the innovator in global biopharmaceuticals with cutting edge technologies to bring biosimilars and new antibody drugs fast to the market and to contribute to the health and well-being of mankind.

OUR PROMISE

To provide affordable biomedicines of superior quality for enhanced treatment access, new cures, and vaccines for life threatening diseases.

OUR CORE VALUES



Pathfinder



Solution Provider



Contributor



Game Changer



Harmonizer

a member of  CANCER MOONSHOT



Global Center

21 Biopolis Road, #04-24
Nucleos South Building, Singapore 138567
Tel: +65 6553 7220

Innovative Discovery Center (IDC)

Prestige Biopharma IDC Co., Ltd.
2776-8, Myeongji-dong, Gangseo-gu,
Busan 618-814, South Korea
Tel: +65 51 580 8000
Email: info@prestigebio.com

Prestige Biologics

197, Osongsaengmyeong 1-ro,
Osong-eup, Heungdeok-gu, Cheongju-si,
Chungcheongbuk-do 28161, South Korea
Tel: +82 43 232 1552
Email: info_pbl@prestigebio.com



PRESTIGE BIOPHARMA